Biogen and Eisai received FDA approval for a new drug formulation aimed at Alzheimer's disease.
7 reports, 6 independent
Updated Jul 14
Gone quiet
Reached 4 outlets in its first 24 hours
- Reports
- 7
- Developments
- 4
- Repetition
- 43%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Biogen and Eisai received FDA approval for a new drug formulation aimed at Alzheimer's disease.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Joint FDA approval of LEQEMBI for Alzheimer’s disease.1 source
Partnership between Biogen and Eisai received FDA approval for a new Alzheimer's drug formulation.1 source
AbbVie launched Vyalev and acquired a drug pipeline, while Biogen and Eisai market Leqembi for AD.1 source
Eisai initiated a rolling sBLA submission for AD treatments alongside Biogen.1 source
Keep exploring
The entities involved
- FDA
-
Biogen
American multinational biotechnology company
Nothing else this week.
-
Eisai
Japanese pharmaceutical company
Nothing else this week.
Related events
- Amylyx Pharmaceuticals is seeking FDA approval for a new drug treatment.
- Avexitide received FDA Breakthrough Therapy designation.
- The FDA recommended advancement for a new drug application submitted by a company.
- BioXcel Therapeutics received FDA approval for its drug and announced results from New Haven.
- The FDA is reviewing a drug approval application for a condition involving the company GAD.
Coverage
Newest first; wire copies grouped- themarketsdaily.com
- benzinga.com
- StockStoryBiogen (BIIB) Stock Trades Down, Here Is Why Shares of biotech company Biogen (NASDAQ:BIIB) fell 3% in the afternoon session after Needham analyst Ami Fadia reiterated a "Hold" rating on the stock. T
- ZacksWill AbbVie's Neuroscience Portfolio Continue to Aid Top-line Growth? AbbVie ABBV has built a robust neuroscience franchise over the years. Though the segment was initially heralded by blockbuster me
- StockStoryBiogen (BIIB) Stock Is Up, What You Need To Know Shares of biotech company Biogen (NASDAQ:BIIB) jumped 4.8% in the afternoon session after the company and its partner Eisai received FDA approval for
- GlobeNewswireEisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease U
- PR Newswire/U P D A T E -- Eisai Inc./ A link has been updated in this news release, FDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzhei